Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $13.00 price target on Taysha Gene Therapies (NASDAQ: TSHA).

The analyst comments "Remain Strong Buy rated on TSHA shares and come away from the company’s 4Q25 earnings call feeling incrementally more confident in management’s articulated plan to file on 6-month REVEAL Part B data. Given the written FDA feedback around equivalency between Part A and Part B product, and given that that Part A patients (n=12) will have a 12-month follow-up, and be included in the BLA, we feel confident that the overall package, once submitted, will be sufficient for filing. With 6-month Part B data anticipated YE26, we assume a 1H27 BLA filing and 4Q27 approval and launch. When combined with a clear risk/reward advantage vis-à-vis competitor NGN-401 and a large, unmet need among the Rett syndrome patient population, we anticipate strong uptake with revenue of $92.2M, $284.0M, $545.6M, and $846.1M for FY27-FY30, respectively. Price target remains $13."

For an analyst ratings summary and ratings history on Taysha Gene Therapies click here. For more ratings news on Taysha Gene Therapies click here.

Shares of Taysha Gene Therapies closed at $4.45 yesterday.